More recently, a 2024 retrospective study involving 73 patients with ALK-rearranged NSCLC reported that patients who continued TKI therapy beyond oligoprogression, especially when combined with LAT, experienced a significant clinical benefit. This evidence concerns the gene ALK and non-small cell lung carcinoma.